KRAS and acute myeloid leukemia: Based on the results from WGS and TCS analysis we identified a unique mutational landscape in pediatric NK-AML characterized by a higher prevalence of mutated CEBPA, FLT3, GATA2, NPM1, PTPN11, TET2, and WT1 as well as a lower prevalence of mutated KIT, KRAS, and NRAS compared with AK-AML (Figure 2 and Figure 3A,B).